Immuneering names former Terns CFO Andrew Gengos as finance chief

Immuneering Corp. Class A

Immuneering Corp. Class A

IMRX

0.00
  • Immuneering appointed Andrew Gengos as chief financial officer, effective July 16, 2026.
  • Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals, which Merck acquired for USD 6.7 billion.
  • He will lead financial strategy, capital allocation, investor relations, business development, corporate development as Immuneering advances Phase 3 candidate atebimetinib.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.